Somnomed Limited (AU:SOM)
ASX:SOM
Want to see AU:SOM full AI Analyst Report?
Top Page
Somnomed Limited
(Sydney:SOM)
Select Model
Select Model
Rating:55Neutral
Price Target:
AU$0.60
▲(7.14% Upside)
Action:Reiterated
Date:06/16/26
The score is mainly supported by improving cash flow and continued revenue growth, alongside a low-leverage balance sheet. Offsetting this are persistent losses (negative margins/ROE), weak technical momentum (negative MACD and below longer-term moving averages), and a negative P/E with no dividend yield data.
Positive Factors
Revenue Growth
Consistent revenue growth (+11.22% latest) indicates expanding adoption of SomnoMed's oral appliance products across its channels. Sustained top-line expansion underpins scale benefits, supports incremental investment in operations and markets, and is a durable signal of demand over the next several months.
Negative Factors
Persistent Net Losses
Persistent negative net profit and EBIT margins mean SomnoMed has yet to convert healthy revenue and gross margins into operating profitability. Sustained losses constrain reinvestment, increase pressure on cash reserves, and require structural improvement to deliver investor returns over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth (+11.22% latest) indicates expanding adoption of SomnoMed's oral appliance products across its channels. Sustained top-line expansion underpins scale benefits, supports incremental investment in operations and markets, and is a durable signal of demand over the next several months.
Read all positive factors
Somnomed Limited (SOM) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$117.21M
Dividend YieldN/A
Average Volume (3M)705.41K
Price to Earnings (P/E)―
Beta (1Y)1.36
Revenue Growth18.21%
EPS Growth65.00%
CountryAU
Employees300
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding219,083,250
10 Day Avg. Volume159,446
30 Day Avg. Volume705,406
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)2.97
Price to Sales (P/S)1.24
P/FCF Ratio25.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.00Price Target Upside78.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Somnomed Limited Business Overview & Revenue Model
Company Description
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDe...
How the Company Makes Money
SomnoMed primarily makes money by selling oral appliance therapy devices (custom-fitted mandibular advancement splints) and associated components that are prescribed for patients with sleep-disordered breathing (notably obstructive sleep apnoea an...
Somnomed Limited Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
58
Neutral
Cash Flow
70
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 118.50M | 111.49M | 91.65M | 83.62M | 72.58M | 62.71M |
| Gross Profit | 68.02M | 66.73M | 55.13M | 45.77M | 39.15M | 33.90M |
| EBITDA | 4.18M | 1.58M | -2.33M | 698.39K | 524.53K | 3.57M |
| Net Income | -2.56M | -3.46M | -12.24M | -8.00M | -4.44M | -1.19M |
Balance Sheet | ||||||
| Total Assets | 79.90M | 80.97M | 69.80M | 62.49M | 58.09M | 56.17M |
| Cash, Cash Equivalents and Short-Term Investments | 18.03M | 17.29M | 16.18M | 11.96M | 15.64M | 21.11M |
| Total Debt | 14.01M | 8.03M | 6.72M | 23.51M | 12.01M | 8.91M |
| Total Liabilities | 29.86M | 34.58M | 24.78M | 40.09M | 30.31M | 24.01M |
| Stockholders Equity | 50.04M | 46.39M | 45.02M | 22.40M | 27.79M | 32.16M |
Cash Flow | ||||||
| Free Cash Flow | 3.71M | 5.36M | -7.72M | -10.29M | -6.93M | -1.43M |
| Operating Cash Flow | 7.85M | 7.78M | -6.33M | -3.88M | 1.86M | 2.71M |
| Investing Cash Flow | -5.98M | -3.98M | -5.34M | -6.41M | -8.47M | -4.37M |
| Financing Cash Flow | -1.56M | -3.38M | 16.68M | 6.61M | 2.09M | -6.80M |
Somnomed Limited Technical Analysis
Negative
0.56
Price Trends
0.57
Negative
0.61
Negative
0.69
Negative
Market Momentum
-0.01
Positive
39.32
Neutral
43.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:SOM, the sentiment is Negative. The current price of 0.56 is below the 20-day moving average (MA) of 0.57, below the 50-day MA of 0.57, and below the 200-day MA of 0.69, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 39.32 is Neutral, neither overbought nor oversold. The STOCH value of 43.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:SOM.
Somnomed Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | AU$7.72B | 22.35 | 17.76% | 1.64% | 2.04% | -6.63% | |
55 Neutral | AU$117.21M | -44.21 | -5.31% | ― | 18.21% | 65.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$2.49B | -12.87 | -890.76% | ― | -0.80% | -249.48% | |
42 Neutral | AU$47.94M | 600.00 | 0.48% | ― | 24.45% | ― | |
42 Neutral | AU$63.03M | -3.20 | -54.48% | ― | 17.24% | -20.00% | |
40 Underperform | AU$23.94M | -1.77 | -180.06% | ― | 74.74% | 4.32% |
* Healthcare Sector Average
AU:SOM
Somnomed Limited
0.54
-0.12
-18.32%
AU:COH
Cochlear
118.03
-171.60
-59.25%
AU:CMP
Compumedics Limited
0.24
-0.02
-5.88%
AU:CYC
Cyclopharm Limited
0.50
-0.43
-46.24%
AU:MX1
Micro-X Ltd.
0.03
-0.02
-36.00%
AU:4DX
4DMedical Ltd
4.16
3.92
1633.33%
Somnomed Limited Corporate Events
SomnoMed Issues 160,000 Unquoted Options Under Employee Incentive Plan
Mar 20, 2026
SomnoMed Limited has notified the Australian Securities Exchange of the issue of 160,000 unquoted options under its employee incentive scheme. The options, carrying no exercise price and expiring on December 1, 2031, were issued on March 20, 2026 ...
SomnoMed Applies to List 160,000 New Ordinary Shares on ASX
Mar 18, 2026
SomnoMed Limited, an ASX-listed healthcare company focused on sleep-related medical solutions, continues to build its presence in the medical technology market with products aimed at patients and clinicians managing sleep disorders.The company has...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.